CRIS Current Research Information System

COJUTTI, PIER GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.675
NA - Nord America 4.284
EU - Europa 3.381
SA - Sud America 443
AF - Africa 168
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.977
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.181
SG - Singapore 1.507
CN - Cina 1.456
VN - Vietnam 1.278
IT - Italia 1.228
DE - Germania 671
HK - Hong Kong 394
GB - Regno Unito 350
BR - Brasile 324
IN - India 296
KR - Corea 248
SE - Svezia 208
FR - Francia 181
NL - Olanda 169
RU - Federazione Russa 148
BD - Bangladesh 124
JP - Giappone 117
IE - Irlanda 99
FI - Finlandia 94
CI - Costa d'Avorio 61
CA - Canada 53
AR - Argentina 51
ID - Indonesia 50
CH - Svizzera 36
ES - Italia 35
ZA - Sudafrica 34
IQ - Iraq 28
AT - Austria 26
PH - Filippine 26
UA - Ucraina 25
AU - Australia 24
MX - Messico 24
PL - Polonia 22
BG - Bulgaria 20
PK - Pakistan 20
SA - Arabia Saudita 18
TH - Thailandia 18
TR - Turchia 18
EC - Ecuador 17
SC - Seychelles 16
TW - Taiwan 15
CL - Cile 12
CO - Colombia 12
PT - Portogallo 12
JO - Giordania 9
MA - Marocco 9
UZ - Uzbekistan 9
VE - Venezuela 8
BE - Belgio 7
CZ - Repubblica Ceca 7
EG - Egitto 7
LT - Lituania 7
NG - Nigeria 7
PY - Paraguay 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
EE - Estonia 6
PE - Perù 6
AZ - Azerbaigian 5
TG - Togo 5
TN - Tunisia 5
CY - Cipro 4
MY - Malesia 4
NP - Nepal 4
UY - Uruguay 4
BH - Bahrain 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
HN - Honduras 3
HR - Croazia 3
IR - Iran 3
MD - Moldavia 3
NI - Nicaragua 3
PA - Panama 3
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CM - Camerun 2
DZ - Algeria 2
GT - Guatemala 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
KE - Kenya 2
LB - Libano 2
MK - Macedonia 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A1 - Anonimo 1
AI - Anguilla 1
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CD - Congo 1
CR - Costa Rica 1
CU - Cuba 1
Totale 13.950
Salva come PNG Salva come JPEG
Città #
Singapore 1.030
Hefei 522
Dallas 497
Ashburn 467
San Jose 377
Hong Kong 367
Ho Chi Minh City 316
Santa Clara 281
Hanoi 260
Fairfield 255
Southend 249
Bologna 245
Seoul 229
Beijing 186
Boardman 158
Princeton 138
Milan 126
Seattle 114
Woodbridge 114
Lauterbourg 113
New York 107
Dong Ket 106
Tokyo 99
Dublin 96
Houston 96
Los Angeles 94
Chandler 93
Cambridge 88
Wilmington 78
Da Nang 73
Rome 71
Abidjan 60
Buffalo 58
Bengaluru 56
Helsinki 53
Ann Arbor 50
Council Bluffs 48
Des Moines 48
Haiphong 44
Chicago 40
Redondo Beach 40
Shanghai 37
Turin 36
Munich 35
Florence 33
Frankfurt am Main 30
Jakarta 28
Redwood City 26
São Paulo 26
Amsterdam 24
San Diego 24
Bern 22
Biên Hòa 22
London 21
Nanjing 21
Nuremberg 21
Lappeenranta 20
Can Tho 19
Guangzhou 19
Modena 19
Mumbai 19
Turku 19
Sofia 18
Tongling 18
Columbus 17
Redmond 17
Atlanta 15
Berlin 15
Bremen 15
Jinan 15
Montreal 15
Naples 15
Orem 15
Vienna 15
Yubileyny 15
Baghdad 14
Bến Tre 14
Brescia 13
Castel Maggiore 13
Hải Dương 13
Mexico City 13
Paris 13
Phoenix 13
San Francisco 13
Toronto 13
Warsaw 13
Chennai 12
Johannesburg 12
Rimini 12
Thái Nguyên 12
Bắc Ninh 11
Genoa 11
Riyadh 11
Thái Bình 11
Verona 11
Changsha 10
Denver 10
Hyderabad 10
Rio de Janeiro 10
Bari 9
Totale 8.565
Salva come PNG Salva come JPEG
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds? 1.180
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 263
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 248
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 245
Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin? 228
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 226
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 224
Epidemiological characteristics and management of Gram-negative bacteraemia in different immunocompromised hosts: Observational single-center study 211
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 201
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 201
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 190
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 187
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data 186
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales 181
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 179
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 175
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 173
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 173
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 172
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. 172
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 168
Covid-19 and the role of smoking: The protocol of the multicentric prospective study COSMO-IT (covid19 and smoking in italy) 164
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 164
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. 164
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 158
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 156
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring 151
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 150
Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections 145
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 144
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 141
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 141
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 139
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 139
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 135
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 133
Population Pharmacokinetics of a Novel Oral Fosfomycin Prophylactic Scheme in the Plasma and Prostate of Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia 132
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 131
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections 130
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization 128
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 128
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 127
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring 124
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring 122
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients 121
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 121
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients 120
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients 120
Role of a TDM-guided strategy of isavuconazole for optimizing efficacy/safety outcomes in onco-hematological pediatric patients: a systematic review 118
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison 114
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 114
Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis 113
Gentamicin once-daily in enterococcal endocarditis 112
Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach 108
Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections 106
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 105
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies 103
Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion 102
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients 102
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 100
Limited sampling strategies for determining the area under the plasma concentration–time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis 99
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: Dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations 99
Reappraisal of linezolid dosing in renal impairment to improve safety 98
Pharmacodynamics of teicoplanin against MRSA 98
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 94
Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient 90
TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient 88
Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? 87
Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies 87
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 87
Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" 83
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? 83
Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies 82
Linezolid underexposure in a patient co-treated with venlafaxine 81
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 80
Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance 80
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 79
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 79
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 77
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: A step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation 77
Drugs and blood cells 75
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures 74
Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6” 73
Does Critical Illness Change Levofloxacin Pharmacokinetics? 72
Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae 72
Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study 71
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 71
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 71
Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round/A Case Study 70
Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa 70
Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? 69
Fast and Sensitive Analysis of Fosfomycin in Human Plasma Microsamples Using Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring 68
Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring 68
Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: Findings from a monocentric, prospective, open-label, interventional study 68
Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients 68
Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency 66
Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity? 65
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 65
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus 64
Totale 13.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.885
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.885
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021201 0 0 0 0 0 0 0 0 0 0 0 201
2021/20221.033 61 22 54 52 163 89 38 78 94 61 138 183
2022/2023920 96 80 46 141 55 42 58 63 169 30 68 72
2023/2024687 54 64 51 76 60 70 75 65 49 67 35 21
2024/20253.054 98 325 241 182 418 132 273 67 42 500 224 552
2025/20267.398 527 1.158 907 598 501 317 1.104 222 934 475 422 233
Totale 14.271